Management of Irbesartan in Patients with Bradycardia

Rationale for Holding Irbesartan in Bradycardia

In patients with heart failure and bradycardia, reducing or stopping RAS inhibitors (including ARBs like irbesartan) is recommended when heart rate is below 60 bpm 1
When managing patients with low blood pressure and bradycardia, guidelines suggest reducing ARBs before other medications if the heart rate is below 60 bpm 1
Bradycardia is defined as a heart rate <60 beats per minute, though clinical significance typically occurs at rates <50 bpm or when symptoms develop 2

Assess for signs of symptomatic bradycardia, including altered mental status, ischemic chest discomfort, acute heart failure, and hypotension 1, 2
If symptomatic bradycardia is present, hold irbesartan immediately and consider atropine for acute management 1, 2
If asymptomatic bradycardia (HR <60 bpm), hold irbesartan and monitor for development of symptoms 1, 2

In the setting of pre-existing bradycardia, ARBs like irbesartan may exacerbate hypotension due to their vasodilatory effects 1
The combination of bradycardia and hypotension can lead to decreased cardiac output and tissue perfusion 3

Continuous cardiac monitoring is essential when managing antihypertensives in patients with bradycardia 1
Monitor for signs of hypoperfusion including altered mental status, dizziness, or worsening symptoms 1
After holding irbesartan, reassess heart rate and blood pressure before considering restarting the medication 2

In patients with tachy-brady syndrome, management may be more complex and require evaluation for underlying causes 2
Patients with chronic bradycardia may require permanent adjustment of their antihypertensive regimen 2
If bradycardia persists despite holding medications, further evaluation for intrinsic conduction system disease may be warranted 2, 4